| birabresib (OTX015) / Merck (MSD) |
NCT01713582: A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001) |
|
|
| Completed | 1 | 141 | NA | OTX015/Birabresib, MK-8628 | Oncoethix GmbH | Acute Myeloid Leukemia, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Multiple Myeloma | 01/17 | 01/17 | | |
NCT02259114: A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) |
|
|
| Completed | 1 | 47 | NA | Birabresib, OTX105, MK-8628 | Oncoethix GmbH | NUT Midline Carcinoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation, Castrate-resistant Prostate Cancer, CRPC, Pancreatic Ductal Adenocarcinoma | 03/17 | 03/17 | | |
NCT02698176 / 2015-005488-18: A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) |
|
|
| Terminated | 1 | 13 | NA | Birabresib, OTX015, MK-8628 | Merck Sharp & Dohme LLC | NUT Midline Carcinoma (NMC), Triple Negative Breast Cancer (TNBC), Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC) | 04/17 | 04/17 | | |
NCT02698189: A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005) |
|
|
| Terminated | 1 | 9 | NA | Birabresib Dose 20 mg, OTX015, MK-8628 | Merck Sharp & Dohme LLC | AML Including AML de Novo and AML Secondary to MDS, DLBCL | 01/18 | 09/21 | | |
